Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Experts, Industry Execs Say Cost Calculation Drug Pricing Method Fraught with Challenges
September 8, 2015
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- Japan’s National Database “World’s Largest in Scale”: Kyoto University Prof. Nakayama
August 20, 2015
- Genome Sequencing Study of Biliary Tract Cancer Suggests Effectiveness of Immune Checkpoint Therapy: National Cancer Center
August 12, 2015
- St. Marianna Univ. Hospital Introduces Tougher Rules for Adopting New Drugs with Emphasis on Cost, Efficacy, and Safety
July 28, 2015
- PD-L1 Expression Key to Decide Whether to Combine Opdivo, Yervoy: Oncologist
July 21, 2015
- Japan, US Oncologists Exchange Barbs over Opdivo Costs
July 21, 2015
- Japan Lung Cancer Society Petitions Health Minister for Early Approval of AZ’s AZD9291 for EGFR-TKI-Resistant NSCLC
July 8, 2015
- NCC Starts PI Study of Nucleic Acid Drug in Treatment-Resistant Locally Advanced or Recurrent Breast Cancer
July 8, 2015
- JSGM to Issue Policy Proposal after MHLW Sets New Target for Generic Market Share
June 17, 2015
- AGs “Will Energize the Generic Drug Market”: Prof. Sakamaki
June 17, 2015
- MHLW Official Urges Generic Drug Makers to Expand into Overseas Markets
June 17, 2015
- MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
- Tiotropium Positioned in Step 3 and Step 4 Care for Asthma: Japanese Society of Allergology’s Revised Guidelines
June 5, 2015
- Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
- Xtandi Monotherapy Meets Primary Endpoint in PII Study for Triple-Negative Breast Cancer: Astellas
June 3, 2015
- 3 of 20 Japanese Gastric Cancer Patients Show PR to PD-L1 Inhibitor Avelumab: ASCO
June 3, 2015
- Ibrance Prolongs PFS in Second-Line for Advanced Breast Cancer: ASCO
June 3, 2015
- BBI608, BBI503 Exert Antitumor Activity in Multiple Studies: Sumitomo Dainippon
June 3, 2015
- Pfizer, Merck KGaA Set to Leverage Complementary Tie-Up to Develop PD-L1 Inhibitor
June 2, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…